GlassScriptPhysician profile
Philip A Romm
NPI 1760478184
$51,838.88
in general payments reported to CMS, 2019-2025
36 companies · $27K in 2025
The $27K reported for 2025 was more than what 94% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $1,829 · 2021: $1,752 · 2022: $2,678 · 2023: $3,064 · 2024: $5,597 · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $21K · Travel and Lodging: $7,397 · Food and Beverage: $6,711.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $21,150.00 |
| Travel and Lodging | $7,397.48 |
| Food and Beverage | $6,711.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $28,387.37 | 2019-2025 | Amplatzer Amulet, Ensite Precision, Cardiomems |
| Amgen INC. | $8,605.92 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $6,482.64 | 2019-2025 | Versacross Access Solution, Avvigo Guidance System, Watchman Flx |
| Penumbra, INC. | $2,711.70 | 2024-2025 | Indigo System |
| Janssen Pharmaceuticals, INC | $635.00 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $591.67 | 2019-2025 | |
| Pfizer INC. | $475.43 | 2019-2025 | |
| Amarin Pharma, INC. | $388.96 | 2019-2021 | |
| Esperion Therapeutics, INC. | $376.77 | 2020-2025 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $329.74 | 2019-2025 | Camzyos, Eliquis |
| Abiomed | $301.56 | 2022-2025 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $253.41 | 2020-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $236.77 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $227.32 | 2020-2025 | Farxiga |
| Sanofi-Aventis U.S. LLC | $225.14 | 2019-2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $214.37 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Inari Medical, INC. | $198.86 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Angiodynamics, INC. | $198.74 | 2024-2025 | Alphavac |
| Bayer Healthcare Pharmaceuticals INC. | $131.80 | 2021-2025 | |
| Edwards Lifesciences Corporation | $131.03 | 2020-2024 | Sapien 3 Ultra Resilia |
| Merck Sharp & Dohme LLC | $115.35 | 2022-2025 | Verquvo |
| Regeneron Healthcare Solutions, INC. | $108.86 | 2019-2021 | |
| W. L. Gore & Associates, INC. | $107.33 | 2021-2024 | Gore Cardioform Septal Occluder |
| Arbor Pharmaceuticals, INC. | $63.94 | 2019-2022 | |
| Chiesi USA, INC. | $49.79 | 2019-2020 | |
| Heartflow, INC. | $45.12 | 2023-2025 | Ffrct |
| Medtronic Vascular, INC. | $39.57 | 2019-2020 | |
| Novo Nordisk INC | $34.99 | 2024 | Rybelsus, Ozempic |
| Lundbeck LLC | $32.51 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $31.04 | 2019-2021 | |
| Gilead Sciences, INC. | $29.00 | 2019 | |
| Scpharmaceuticals INC. | $22.04 | 2025 | |
| Glaxosmithkline, LLC. | $16.50 | 2025 | Arexvy, Shingrix |
| Daiichi Sankyo INC. | $14.13 | 2019 | |
| Baylis Medical Company INC | $12.46 | 2021 | |
| Aegerion Pharmaceuticals, INC. | $12.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Romm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.